Skeptic critique for analysis AD-MASTER-PLAN-APOE-20260428030754: AD Master Plan preregistration: APOE
The analysis question is substantive, but the current record does not by itself prove the claim. The main dissent is: APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality.
The debate should reject overclaiming in three forms. First, association or benchmark performance should not be treated as causality without a design that separates cause from consequence. Second, a positive average effect can hide subgroup failure across APOE, AD, tau, amyloid. Third, an analysis that lacks provenance, environment capture, or preregistered endpoints can produce plausible but non-reproducible conclusions.
A decisive falsifier would be failure of compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts to move the predicted proximal endpoint under adequate power and controls. The strongest alternative explanation is that the observed signal is a disease-stage marker, prompt or notebook artifact, or compensatory response rather than an upstream driver.